Michael Manos, PhD
Treatment & Services
- Acceptance Commitment Therapy
- Adolescent Health
- Behavioral Intervention
- Center for Pediatric Behavioral Health
- Parent Guidance and Training
- Pediatric Behavioral Medicine
- Pediatric Neuroscience
Specialty in Diseases & Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Attention Deficit Hyperactivity Disorder (ADHD), Adult
Insurance
Is Cleveland Clinic Part of Your Insurance?
Review a list of accepted insurance plans for our Northeast Ohio locations or learn more about purchasing a contracted managed care plan.
View All PlansAbout Michael Manos, PhD
Michael J. Manos, PhD, is staff psychologist in the Center for Pediatric Behavioral Health, Pediatric Institute, Cleveland Clinic. He is the founding Clinical and Program Director of the pediatric and adult ADHD Center for Evaluation and Treatment of Cleveland Clinic in Cleveland, Ohio. He is Adjunct Faculty in Case Western Reserve University School of Medicine, Department of Psychiatry.
Dr. Manos has worked for more than 25 years in pediatric psychology, special education, and child and adolescent psychiatry. He has authored or contributed to scientific articles and informative book chapters on the diagnosis and treatment of attention deficit/hyperactivity disorder. He also has presented numerous papers and symposia on child and adolescent behavior disorders.
Dr. Manos is a member of several professional organizations, including the American Psychological Association, the American Psychological Society, and the Association for Behavior Analysis International and Association for Contextual Behavioral Science.
Additional Publications
Manos M, Frazier TW, Landgraf JM, Weiss M, Hodgkins P. (2009). Health-related quality of life and medication satisfaction in children with ADHD treated with the methylphenidate transdermal system. Current Medical Research & Opinion; 25(12):3001–3010. Also posted CMRO EarlyOnline 23 Oct.
Manos MJ, Brams M, Childress A, Findling RL, López FA, Jensen PS. (In press). Changes in emotions related to medication used to treat Attention-Deficit/Hyperactivity Disorder. Part I: A literature review. J Atten Disord.
Findling RL, Brams M, Childress A, López FA, Manos MJ, Jensen PS. (In press). Changes in emotions related to medication used to treat Attention-Deficit/Hyperactivity Disorder. Part II: Clinical approaches. J Atten Disord.
Cerulli T, Cohen L, Goodman D & Manos M. (2009). Panel discussion: Evaluating ADHD and subtype disorders / Individualizing therapy for patients with ADHD / Minimizing the risk associated with prescribing controlled substances while maximizing patient outcome / Assessing outcomes in patients with ADHD / Considerations for selecting an appropriate ADHD therapy. The Journal of Medicine, 2(4), 213-230.
Manos M. (2009). ADHD & Comorbid Depression in Adults. The Case for Emerging Pharmacotherapies in ADHD, Continuing Medical Education & accredited 16-page supplement, CNS Spectrums, November.
Manos, M. (2009). Nuances in initiating stimulant treatment for children with ADHD. The Year In ADHD, Editor-in-chief Anthony Rostain, Current Medicine Group, 1, 1-4.
Wilens TE, Boellner SW, López FA, Turnbow JM, Wigal SB, Childress AC, Abikoff HB, Manos MJ. (2008). Varying the wear time of the methylphenidate transdermal system in children with attention deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 47:6, 700-708.
Arnold LE., Amato A., Bozzolo H., Hollway J., Cook A., Ramadan Y., Crowl L., Zhang D., Thompson S., Testa J., Kliewer V., Wigal T., McBurnett K., Manos M. (2007). Acetyl-L-carnitine (ALC) in attention-deficit/hyperactivity disorder (ADHD): A multi-site, placebo-controlled pilot trial. Journal of Child and Adolescent Psychopharmacology, 17, 791-801.
Manos, M. (2007). Pharmacologic Treatment of ADHD: Road Conditions in Driving Patients to Successful Outcomes. Translated into Ukrainian. Ukrainian medical journal: NeuroNEWS: Psychoneurology and Neuropsychiatry.
Manos, M. (2007). Pharmacologic Treatment of ADHD: Road Conditions in Driving Patients to Successful Outcomes. Clinical Review, The Medscape Journal of Medicine, online journal. www.medscape.com/welcome/journals.
Manos, M., Tom-Revzon, C., & Bukstein O. (2007). Changes and challenges: Managing ADHD in a fast-paced world. Journal of Managed Care Pharmacy, (supplement), 13(9), 2-16.
Findling RL, Short EJ, McNamara NK, Demeter CA, Stansbrey RJ, Gracious BL, Whipkey R, Manos MJ, Calabrese JR. (2007). Methylphenidate in the treatment of children and adolescents with bipolar disorder and attention deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 46, 1445-1453.
Short, E., Fairchild, L., Findling, R., Manos, M. (2007). Developmental and subtype differences in behavioral assets and problems in children diagnosed with ADHD. Journal of Attention Disorders, 10(1), 1-9.
Caserta, D., Manos, M., Shiever, K. (2006). Beyond empirical support: Taking the Summer Treatment Program and lessons learned from the MTA into the clinical realm. Report on Emotional & Behavioral Disorders in Youth, 7(1), 9-12.
Aguirre, A.M., Short, E., Pelham, W., Caserta, D., Manos, M. (2006). Influence of setting on academic and behavioral performance of children diagnosed with ADHD. Advances in ADHD.1(1), 16-22.
Manos, M., Opperman, J., Heikkila, L., Heikkila, K. (2005). Voices of the collaboration team: Comments for the pediatric neurologist. Seminars in Pediatric Neurology. 12(4), 259-267.
Pelham W. Jr., Manos M., Ezzell C., Tresco K., Gnagy E., Hoffman M., Onyango A., Fabiano G., Lopez-Williams A., Wymbs B., Caserta D., Chronis A., Burrows-MacLean L., Morse G. (2005) A Dose-Ranging Study of a Methylphenidate Transdermal System in Children with ADHD. Journal American Academy of Child and Adolescent Psychiatry. 44(4), 522-529.
Short E., Manos, M., Findling, R., and Schubel, E. (2004). A Prospective Study of Stimulant Response in Preschoolers: Insights from ROC Analyses. Journal American Academy of Child and Adolescent Psychiatry 43(3), 251-259
Fabiano, G., Pelham, Jr., W., Manos, M., Gnagy, E., Chronis, A., Onyango, A., Williams, A., Burrows-MacLean, L., Coles, E., and Meichenbaum, D. (2004). An evaluation of three time-out procedures for children with attention-deficit/hyperactivity disorder. Behavior Therapy, 35(3), 449-469.
Wilens TE, Rosen DJ, McGough J, Sallee FR, Swanson JM, Manos MJ. (2004). Part 1. Pediatric ADHD: Clinical criteria for diagnosis and management. Primary Psychiatry, 11(2):1-11.
Manos M. and Short, E. (2003). Dose response curves in clinical titration of stimulants: The case for care in treating ADHD. Abstract. Journal of Developmental and Behavioral Pediatrics 24(5), 396
Faraone S., Short E., Biederman, J., Findling R., Roe, C., and Manos M. (2002). Efficacy of Adderall™ and methylphenidate in Attention-Deficit/Hyperactivity Disorder: A drug-placebo and drug-drug response curve analysis of a naturalistic study. International Journal of Neuropsychopharmacology, 5(2), 121-129
Findling, R., Short E., Manos, M., (2002). Special Report: Optimizing ADHD treatment. The Psychiatric Times. XIX, 9.
Findling, R., Short E., Manos, M., (2001). Developmental aspects of psychostimulant treatment in children and adolescents with Attention Deficit/Hyperactivity Disorder. Journal American Academy of Child & Adolescent Psychiatry, 40(12), 1441-1447
Findling R., Short E., Manos, M. (2001). The short-term cardiovascular effects of methylphenidate and Adderall. Journal American Academy of Child & Adolescent Psychiatry, 40(5), 525-529.
Manos, M., Short, E., Findling, R., (2000). Dose response curves across ADHD subtypes: Differential effects between Adderall® and methylphenidate (Abstract). Colwood Healthworld Clinical Opinion Series, Advancing ADHD Management and Treatment. A. Zametkin (ed.), Continuing Medical Education, University of Wisconsin
Manos, M.J., Short, E.J., & Findling, R.L. (2000). Dose Response Curves Across ADHD Subtypes: Differential Effects Between Adderall and Methylphenidate. Pediatric Research, 45(4), 30A.
Manos, M., Short, E., Findling, R., (1999). Differential effectiveness of methylphenidate and Adderall® in school-aged children with Attention Deficit/ Hyperactivity Disorder. Journal American Academy of Child & Adolescent Psychiatry, 38(7), 813-819
Sunshine, JL., Lewin, JS., Wu, DH., Findling, RL., Manos, M., Schwartz, MA., (1997). Functional MRI to localize sustained visual attention activation in-patients with ADHD—A pilot study. American Journal of Neuroradiology, 18, 633-637.
Findling, R., Schwartz, Ma, Flannery, D., Manos, M., (1996). Venlafaxine in adults with attention-deficit/hyperactivity disorder: An open clinical trial. Journal of Clinical Psychiatry, 57(5), 184-189.
Mokuau, N., Manos, M., (1989). A behavioral model for training parents. Social Casework, 70(8), 479-487
Higa, G., Manos, M., Yempuku, A., (1987). Social skills assessment of disadvantaged and mainstream youth. Pacific Educational Research Journal, 3(1), 19-31.
Manos, M. (1983). The effects of verbal elaborations and social reinforcement on children’s discrimination learning. Education and Treatment of Children 6(3), 263-275.
Mace, F. C., Cancelli, A. A., Manos, M. (1983). Increasing teacher delivery of contingent praise and contingent materials using consultant feedback and praise. School Psychology Review, 12(3), 340-346.
Education & Professional Highlights
Appointed
1999
Education & Fellowships
Fellowship - University Hospitals of Cleveland
Psychology
Cleveland,
OH United States
1996
Medical Education - University of Arizona
Special Ed. - Clinical Psychology
Tucson,
AZ
1981
Internship - University of California Los Angeles, Neuropsychiatric Institute
Los Angeles,
CA
1979
Graduate School - John Carroll University
psychology/special education
University Heights,
OH United States
1976
Undergraduate - Northwestern University
Evanston,
IL
1973
Specialty Interests
adults with ADHD, attention deficit hyperactivity disorder, behavioral pediatrics, clinical behavioral pediatrics, family management, pharmacotherapy research
Awards & Honors
- 2007 Keith Conners Award for Scholarly Contribution. Paper published in Journal of Attention Disorders. Developmental and subtype differences in behavioral assets and problems in children diagnosed with ADHD.
- 2006 Chairmen’s Award for Commitment to Clinical Research. Children’s Hospital, Cleveland Clinic, Cleveland, OH.
- 1983 Promising Researcher. Prevention Research Branch, Division of Special Mental Health Programs, National Institute of Mental Health, Rockville, MD.
Industry Relationships
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 4/30/2024, Dr. Manos has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.
* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.
